Clinical features and KRAS mutation in colorectal cancer with bone metastasis.

Sci Rep · 2020 · PMC7713114 · PMID 33273596

Europe PMC DOI

hedged sentence

0.0680

closest p · 1.4× alpha

0.0680

boldest claim

The sentences

marginally significantP = 0.068so close (0.05 < p ≤ 0.1)

KRAS mutation status was a marginally significant factor affecting TTB (median TTB, KRAS wild-type or mutation: 29 or 25.8 months, respectively, P = 0.068).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.